Printer Friendly

BEHRINGWERKE, HOECHST-ROUSSEL COMMENCE ACTION AGAINST IMMUNEX

 BEHRINGWERKE, HOECHST-ROUSSEL COMMENCE ACTION AGAINST IMMUNEX
 WILMINGTON, Del., June 9 /PRNewswire/ -- Behringwerke, A.G., the German pharmaceutical company, and its U.S. affiliate, Hoechst-Roussel Pharmaceuticals Inc., announced today that they had commenced an action in the U.S. District Court for the District of Delaware against Immunex Corporation seeking, among other things, injunctive relief barring Immunex from terminating or otherwise breaching certain contractual relationships under which Hoechst-Roussel markets GM-CSF in the United States.
 GM-CSF is a biotechnology drug that is used to stimulate production of white blood cells in cancer patients who have undergone bone marrow transplants. The product is sold by Hoechst-Roussel under the tradename Prokine, and by Immunex under the tradename Leukine. The complaint alleges that Immunex's conduct constitutes a violation of the federal antitrust laws and that, unless enjoined, it will eliminate competition in the sale of this important new drug, resulting in substantially increased prices to cancer patients and others.
 Immunex previously commenced an action against Hoechst-Roussel and Behringwerke in Washington State court which Hoechst-Roussel and Behringwerke intend to vigorously contest. A spokesperson for Behringwerke stated, "We regret that the actions initiated by Immunex have led to this turn of events, but we have spent substantial amounts developing this product and are resolute in our determination to protect our contractual rights."
 -0- 6/9/92
 /CONTACT: Andrea Stine, 908-231-3752, for Hoechst-Roussel/
 (IMNX) CO: Behringwerke, A.G.; Hoechst-Roussel Pharmaceuticals Inc.; Immunex
 Corporation ST: Delaware, New Jersey, Washington IN: MTC SU:


KD -- NY065 -- 8532 06/09/92 17:14 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1992
Words:252
Previous Article:SAAB CARS USA DEDICATES NEW CORPORATE HEADQUARTERS
Next Article:USA TODAY TO ACCEPT FREE STANDING INSERTS IN PITTSBURGH MARKET
Topics:


Related Articles
IMMUNEX SUES HOECHST FOR BREACH OF CONTRACT, BUSINESS INTERFERENCE, UNFAIR COMPETITION; PROJECTS QUARTER LOSS DUE TO REDUCED GM-CSF SALES
IMMUNEX, HOECHST SETTLE CONTRACT DISPUTE, REVISE GLOBAL COLLABORATION
CPMP RECOMMENDS APPROVAL OF IMMUNEX' GM-CSF IN EUROPEAN COMMUNITY
COURT RULES IN FAVOR OF ALZA & HOECHST MARION ROUSSEL
HOECHST MARION ROUSSEL RECEIVES FAVORABLE DECISION IN SELDANE PATENT SUIT
HOECHST MARION ROUSSEL, ALZA CORPORATION AND CIBA-GEIGY SETTLE NICOTINE PATCH PATENT LITIGATION
Hoechst Marion Roussel and Transkaryotic Therapies Respond to Amgen Patent Suit
Hoechst Marion Roussel and Transkaryotic Therapies Seek Dismissal of Amgen Patent Suit
Hoechst Marion Roussel Announces Stipulation With Andrx in Patent Lawsuit Involving Cardizem(R) CD
Andrx-Hoechst Sued in Michigan Class Action by Cardizem CD Users Charging Price Fixing and Conspiracy to Keep Generic Competitors Off Market

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters